These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 1322237)
1. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237 [TBL] [Abstract][Full Text] [Related]
2. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916 [TBL] [Abstract][Full Text] [Related]
3. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413 [TBL] [Abstract][Full Text] [Related]
4. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival. Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333 [TBL] [Abstract][Full Text] [Related]
5. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731 [TBL] [Abstract][Full Text] [Related]
6. The detection of quantitative serum p53 protein in lung cancer. Sen E; Gönüllü U; Akar N Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881 [TBL] [Abstract][Full Text] [Related]
7. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113 [TBL] [Abstract][Full Text] [Related]
8. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037 [TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis]. Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638 [TBL] [Abstract][Full Text] [Related]
10. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410 [TBL] [Abstract][Full Text] [Related]
11. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients. Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123 [TBL] [Abstract][Full Text] [Related]
13. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. von Brevern MC; Hollstein MC; Cawley HM; De Benedetti VM; Bennett WP; Liang L; He AG; Zhu SM; Tursz T; Janin N; Trivers GE Cancer Res; 1996 Nov; 56(21):4917-21. PubMed ID: 8895744 [TBL] [Abstract][Full Text] [Related]
14. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451 [TBL] [Abstract][Full Text] [Related]
15. P53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy. Bergqvist M; Brattström D; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Wagenius G; Brodin O Anticancer Res; 1998; 18(3B):1999-2002. PubMed ID: 9677456 [TBL] [Abstract][Full Text] [Related]
16. [Correlation between p53 gene mutation and protein expression in 30 cases of human lung cancer]. Zhang J; Zheng J; Fang W Zhonghua Yi Xue Za Zhi; 1998 Nov; 78(11):846-9. PubMed ID: 11038779 [TBL] [Abstract][Full Text] [Related]
17. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis. Kawasaki H; Ogura T; Yokose T; Nagai K; Nishiwaki Y; Esumi H Hum Pathol; 2001 Oct; 32(10):1043-9. PubMed ID: 11679937 [TBL] [Abstract][Full Text] [Related]
18. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas. Forslund A; Kressner U; Lindmark G; Inganäs M; Lundholm K Int J Oncol; 2001 Sep; 19(3):501-6. PubMed ID: 11494027 [TBL] [Abstract][Full Text] [Related]
19. Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer. Lang SM; Stratakis DF; Freudling A; Ebelt K; Oduncu F; Hautmann H; Huber RM Eur J Med Res; 2000 Aug; 5(8):341-6. PubMed ID: 10958767 [TBL] [Abstract][Full Text] [Related]